A5074466929- Health Systems, Economic Evaluations, Quality of Life
- Economic and Financial Impacts of Cancer
- Colorectal Cancer Treatments and Studies
- Opioid Use Disorder Treatment
- Chronic Myeloid Leukemia Treatments
- Chronic Disease Management Strategies
- Lymphoma Diagnosis and Treatment
- Pressure Ulcer Prevention and Management
- Genetic factors in colorectal cancer
- Pharmaceutical Economics and Policy
- Pharmaceutical Practices and Patient Outcomes
- Acute Lymphoblastic Leukemia research
- Diabetic Foot Ulcer Assessment and Management
- Dementia and Cognitive Impairment Research
- Economic and Environmental Valuation
- Medication Adherence and Compliance
- Minimally Invasive Surgical Techniques
- Orthopedic Infections and Treatments
- Biosimilars and Bioanalytical Methods
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Health Policy Implementation Science
- Ion Channels and Receptors
- Retinal Diseases and Treatments
- Palliative Care and End-of-Life Issues
- Surgical Simulation and Training
St. Vincent's Hospital
2024
University of Houston
2020-2023
University of Southern California
2018-2021
University of York
2021
University of Maryland, College Park
2021
New York University
2016
Introduction Concerns have been raised about the limited health system capacity for identification of patients who are eligible a disease-modifying Alzheimer's treatment (DMT). Blood-based biomarker (BBBM) tests promising tool to improve triaging at primary care level. We projected their impact on cost and wait times during diagnostic process. Methods compare four scenarios level from perspective U.S. system: (1) cognitive test only (Mini Mental State Examination [MMSE]), (2) BBBM only, (3)...
Objective: Chronic wounds represent a highly prevalent but little recognized condition with substantial implications for patients and payers. While better wound care products treatment modalities are known to improve healing rates, they inconsistently used in real-world practice. Predicting rates of chronic comparing actual could be detect reward quality care. We developed prediction model healing. Approach: analyzed electronic medical records (EMRs) 620,356 various etiologies 261,398 from...
BackgroundNew regimens have emerged as third-line or later therapies for metastatic colorectal cancer (mCRC), including regorafenib dose optimization (ReDO), trifluridine/tipiracil and bevacizumab (TAS-BEV) combination therapy, fruquintinib. We evaluated relative cost-effectiveness of these in patients with mCRC from a US payer's perspectiveMaterials MethodsA partitioned survival model (PSM) was constructed to estimate total costs quality-adjusted life years (QALYs). Clinical parameters were...
This study aimed to assess the total cost of care (TCC) and budget impact introducing 12-month fixed duration venetoclax + obinutuzumab (VEN+G) as first-line treatment for chronic lymphocytic leukemia (CLL) from perspective a US health plan with 1,000,000 (1M) members. The 3-year model included following comparators: fludarabine cyclophosphamide rituximab (FCR), bendamustine (BR), chlorambucil (GClb), ibrutinib (Ibr), Ibr+Rituximab/obinutuzumab [Ibr+R/Ibr+G]). TCC US-specific costs...
While the initial hospitalization accounts for 75% of total healthcare costs during first 100 days following hematopoietic stem cell transplantation (HSCT), there is a lack studies evaluating considerable variation in cost estimates. Using National Inpatient Sample (NIS) database from 2012-2014, we identified 1832 adult non-Hodgkin lymphoma (NHL) patients who received autologous or allogeneic HSCT and examined complications as predictors hospital cost. Complications occurred >70% patients,...
Recent phase 2 trials have provided data supporting regorafenib dose optimization (ReDO) and trifluridine/tipiracil (TAS-102) with bevacizumab (TAS-BEV) as treatment options in refractory metastatic colorectal cancer (mCRC). Historically, standard (RSD) TAS-102 been utilized third-line mCRC. Given the incorporation of ReDO TAS-BEV options, we sought to evaluate relative cost-effectiveness vs. RSD, TAS-102, for mCRC from a payer perspective.A Markov model was constructed estimate total costs...
Background:: Recent trials suggest that disease-modifying therapy (DMT) for Alzheimer’s disease may become available soon. With the expected high price and a large patient pool, budget impact will be substantial. Objective: We explore combinations of effectiveness under which DMT is cost-effective. Methods: used an open-source model to conduct two-way scenario analyses both payer societal perspectives, varying price, treatment effect size simultaneously. The analysis generates...
Background With the rapid demographic change in Korea, Alzheimer's disease has become a primary concern. Recent developments disease-modifying therapies provide hope that therapy may available soon. The high prevalence and complex evaluation process will create challenges for healthcare system already burdened by current pandemic. This study examined preparedness of South Korean to identify treat patients when such becomes available. Methods We used Markov model simulate stylized patient's...
This retrospective study aimed to examine the safety and clinical outcomes of enhanced recovery after single-site robotic staging surgery in patients with endometrial cancer.Data were collected from Seoul St. Mary's Hospital's electronic medical records between July 2017 August 2021.All included cancer underwent followed by based on guidelines for society recommendations.The factors assessed survival outcomes, complications postoperative adjuvant therapy.Of 60 this study, four (6.7%)...
3525 Background: Recent clinical trials support regorafenib dose optimization (ReDO), a combination therapy with trifluridine/tipiracil and bevacizumab (TAS-BEV), fruquintinib (FRUQ) for the treatment of refractory metastatic colorectal cancer (mCRC). This study evaluated relative cost-effectiveness ReDO, TAS-BEV, FRUQ mCRC from payer perspective in United States. Methods: A Markov model was constructed to estimate total costs quality-adjusted life years (QALY) each treatment. In base case,...
7065 Background: JAK inhibitors (JAKi) are a mainstay of MF treatment, with proven ability to improve symptoms and spleen volume for most pts; although safety profiles vary, some approved JAKi have associated hematologic toxicity. The JAK1/JAK2/ACVR1 inhibitor MMB has shown consistent benefit in improving anemia, symptoms, pts MF. Clinical trials directly compared ruxolitinib, showing more favorable toxicity profile. However, there limited data comparing vs other such as FED. We performed an...
Patients who are exposed to immunosuppressant medication and antiresorptive therapy such as bisphosphonates present an important risk for developing osteonecrosis, notably in the jaws.Osteonecrosis is a complex disease still not well understood which involve different cell-types.This case reports implant placement 69-yearold female presented avascular necrotic bone localized anterior mandible.The patient had medical history of liver transplant osteoporosis.A 14-month follow-up, after...
Abstract Objective To understand the physician perspective on barriers and facilitators of implementing nine different opioid risk mitigation strategies (RMS) when prescribing medications. Methods We created dispersed a cross-sectional online survey through Qualtrics© data collection platform among nationwide sample physicians licensed to practice medicine in United States who have prescribed an medication within past year. The responses were analyzed using deductive thematic analysis...